Commercial Launch of HYLENEX for use in Pediatric Rehydration anounced by Baxter
a new drug for use in Pediatric Rehydration
the question is with all drug how long must the clock tick before it becomes available in the most neediest of places, at a price point that makes it affordable to be subsidized by agencies. Perhaps we should have a site that is a virtual wall of timers each labeled with a drug count the years before the neediest op people are able to benefit.
BOSTON – October 5, 2009— Baxter International Inc. (NYSE: BAX) today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein. This allows for rapid treatment initiation and delivery of intravenous (IV)-like fluid rates, which can help lead to successful rehydration of children in a less invasive manner. Additionally, data from Baxter’s Increased Flow Utilizing Subcutaneously-Enabled (INFUSE) PEDS 1 study are debuting today in the preeminent pediatric journal, Pediatrics. The study was designed to assess the efficacy, safety and clinical utility of HYLENEX recombinant-facilitated subcutaneous rehydration in mild to moderately dehydrated children ages two months to 10 years. This approach was found to be effective, easy to use and well-tolerated. 1 Baxter licensed HYLENEX, the first and only recombinant human hyaluronidase, from Halozyme Therapeutics, Inc. (Nasdaq: HALO)…..